|
|
|
Insider
Information: |
Paul Steven M |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
1,185,025 |
|
Indirect Shares
|
632,151 |
|
|
Direct
Value |
$39,384,943 |
|
|
Indirect Value
|
$32,026,074 |
|
|
Total
Shares |
1,817,176 |
|
|
Total
Value |
$71,411,017 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-09-27 |
5 |
GA |
$0.00 |
$0 |
I/I |
10,314 |
50,540 |
0 |
- |
|
KRTX |
Karuna Therapeutics, Inc. |
|
|
2024-03-18 |
4 |
D |
$330.00 |
$3,496,680 |
D/D |
(10,596) |
0 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2008-02-01 |
4 |
D |
$51.52 |
$575,684 |
D/D |
(11,174) |
70,122 |
0 |
- |
|
KRTX |
Karuna Therapeutics, Inc. |
CSO and President of R&D |
|
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
11,400 |
11,400 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-10-14 |
4 |
D |
$52.54 |
$639,149 |
D/D |
(12,165) |
28,662 |
|
- |
|
LLY |
Eli Lilly & Co |
officerTitle |
|
2005-12-15 |
4 |
OE |
$34.59 |
$453,475 |
D/D |
13,110 |
90,202 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-02-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,579 |
40,040 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-02-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,579 |
15,649 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2020-12-18 |
4 |
AS |
$140.00 |
$2,100,000 |
D/D |
(15,000) |
1,000 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2022-04-01 |
4 |
AS |
$166.04 |
$2,560,371 |
D/D |
(15,000) |
1,000 |
0 |
% |
|
ALNY |
Alnylam Pharmaceuticals I... |
Director |
|
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2009-02-02 |
4 |
D |
$36.82 |
$567,102 |
D/D |
(15,402) |
42,407 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2010-02-01 |
4 |
D |
$35.20 |
$610,790 |
D/D |
(17,352) |
38,897 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-09-27 |
4 |
OE |
$14.66 |
$274,095 |
D/D |
18,700 |
39,204 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-10-14 |
4 |
OE |
$23.41 |
$461,783 |
D/D |
19,728 |
40,827 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2008-02-04 |
4 |
S |
$51.49 |
$1,022,881 |
D/D |
(19,822) |
50,300 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2015-04-01 |
4 |
S |
$48.51 |
$970,200 |
D/D |
(20,000) |
783,650 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
Director |
|
2015-05-01 |
4 |
AS |
$53.31 |
$1,066,200 |
D/D |
(20,000) |
763,650 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2015-06-01 |
4 |
AS |
$71.36 |
$1,446,799 |
D/D |
(20,000) |
743,650 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2015-07-01 |
4 |
AS |
$67.46 |
$1,388,028 |
D/D |
(20,000) |
723,650 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2015-08-03 |
4 |
AS |
$66.42 |
$1,341,692 |
D/D |
(20,000) |
703,650 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2015-09-01 |
4 |
AS |
$52.10 |
$1,048,184 |
D/D |
(20,000) |
683,650 |
0 |
- |
|
LLY |
Eli Lilly & Co |
officerTitle |
|
2006-01-20 |
4 |
A |
$57.04 |
$1,230,011 |
D/D |
21,564 |
98,656 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2006-04-21 |
4 |
S |
$52.80 |
$1,320,000 |
D/D |
(25,000) |
64,656 |
|
- |
|
131 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|